HYDROCORTISONE SODIUM SUCCINATE
Clinical safety rating: avoid
CYP3A4 inducers (eg phenytoin) may decrease efficacy and inhibitors may increase effects Can cause hyperglycemia and adrenal suppression with prolonged use.
Hydrocortisone sodium succinate is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to produce anti-inflammatory, immunosuppressive, and anti-stress responses. It inhibits phospholipase A2, reducing prostaglandin and leukotriene synthesis.
| Metabolism | Hepatic metabolism primarily via 11β-hydroxysteroid dehydrogenase and CYP3A4, producing inactive metabolites (tetrahydrocortisol, cortisone, tetrahydrocortisone) that are conjugated and excreted renally. |
| Excretion | Renal (90-95% as metabolites, <5% unchanged); biliary/fecal <5% |
| Half-life | 1.5-2 hours (plasma terminal); biological half-life 8-12 hours (due to intracellular effects), requiring q6-8h dosing in adrenal insufficiency |
| Protein binding | 90-95% (corticosteroid-binding globulin and albumin) |
| Volume of Distribution | 0.4-0.6 L/kg; distributes into total body water, low tissue binding |
| Bioavailability | IV: 100%; IM: ~80-90% (succinate ester hydrolyzed to active cortisol); not available orally |
| Onset of Action | IV: immediate (minutes); IM: 1-2 hours; oral: 2-4 hours (not applicable as succinate ester is only IV/IM) |
| Duration of Action | IV/IM: 12-24 hours (duration of HPA suppression); clinical effects persist beyond plasma half-life due to genomic actions |
| Molecular Weight | 484.52 |
100–500 mg IV or IM every 2–6 hours, as needed; typical initial dose 100–250 mg IV bolus followed by 100–250 mg IV every 4–6 hours for acute conditions.
| Dosage form | INJECTABLE |
| Renal impairment | No specific dose adjustment required for acute dosing; monitor for fluid retention and hypertension in severe renal impairment (GFR <30 mL/min). |
| Liver impairment | For Child-Pugh Class C, reduce dose by 50% and monitor for signs of glucocorticoid excess; Class A/B no adjustment necessary. |
| Pediatric use | Children: 0.56–8 mg/kg/day IV or IM divided every 6–8 hours; status asthmaticus: loading dose 4–8 mg/kg IV then 1–2 mg/kg every 6 hours. |
| Geriatric use | Initiate at low end of adult dose (e.g., 100 mg IV) due to increased risk of osteoporosis, hyperglycemia, and immunosuppression; monitor for fluid and electrolyte disturbances. |
| 1st trimester | Corticosteroids such as hydrocortisone are associated with a small increased risk of orofacial clefts when used in the first trimester. Use only if clearly needed and benefit outweighs risk. |
| 2nd trimester | Use with caution; may cause fetal growth restriction with prolonged use. Monitor fetal growth if used chronically. |
| 3rd trimester | Use near term may suppress fetal adrenal function; infants should be monitored for adrenal insufficiency after birth. Use only if benefit justifies risk. |
Clinical note
CYP3A4 inducers (eg phenytoin) may decrease efficacy and inhibitors may increase effects Can cause hyperglycemia and adrenal suppression with prolonged use.
| FDA category | Positive |
| Placental transfer | Hydrocortisone crosses the placenta; the placenta may convert it to cortisone, reducing fetal exposure. With high maternal doses, significant transfer can occur, potentially affecting fetal adrenal function. |
■ FDA Black Box Warning
No FDA black box warning specifically for hydrocortisone sodium succinate. However, systemic corticosteroids are associated with increased risk of serious infections, suppression of the hypothalamic-pituitary-adrenal (HPA) axis, and growth retardation in children.
| Common Effects | adrenal insufficiency |
| Serious Effects |
Systemic fungal infectionsHypersensitivity to hydrocortisone or any componentAdministration of live or live-attenuated vaccines (due to immunosuppression)
| Precautions | HPA axis suppression and adrenal crisis upon withdrawal after prolonged therapy, Increased risk of infections (bacterial, viral, fungal, parasitic) and reactivation of latent tuberculosis, Masking of signs of infection (suppression of inflammation), Cushing's syndrome with prolonged use, Osteoporosis, avascular necrosis of bone, Gastrointestinal perforation (especially in diverticulitis, peptic ulcer, colitis), Psychiatric disturbances (euphoria, depression, psychosis), Increased intraocular pressure, glaucoma, cataracts, Thrombotic events (including thrombophlebitis), Growth suppression in children, Fluid and electrolyte disturbances (sodium retention, potassium loss) |
Loading safety data…
| Breastfeeding | Hydrocortisone sodium succinate is excreted into breast milk in low amounts. At typical maternal doses, it is unlikely to cause adverse effects in the breastfed infant. However, with high doses or prolonged use, monitor infant for adrenal suppression. Use the lowest effective dose for the shortest duration. |
| Lactation Rating | L2 (Safer) |
| Teratogenic Risk | First trimester: Increased risk of cleft palate at doses >10 mg/day prednisone equivalent; second/third trimester: Fetal adrenal suppression, intrauterine growth restriction, premature birth with chronic high doses. |
| Fetal Monitoring | Monitor maternal blood pressure, blood glucose, electrolytes; fetal growth ultrasound for IUGR; fetal heart rate monitoring; assess for signs of adrenal suppression in newborn after prolonged exposure. |
| Fertility Effects | May impair ovulation and spermatogenesis at high doses; reversible upon dose reduction or discontinuation. |
| Food/Dietary | Avoid grapefruit and grapefruit juice as they may increase corticosteroid effects. Limit sodium intake to reduce fluid retention and hypertension. Increase potassium-rich foods (bananas, oranges) if hypokalemia occurs. No significant food interactions beyond this. |
| Clinical Pearls | Hydrocortisone sodium succinate is a water-soluble ester of hydrocortisone, allowing rapid IV/IM administration for acute corticosteroid replacement or anti-inflammatory/immunosuppressive effects. For stress-dose coverage in adrenal insufficiency, administer 50-100 mg IV push followed by continuous infusion or q6h dosing. Taper dose gradually after prolonged therapy (>2 weeks) to avoid adrenal crisis. Monitor for hyperglycemia, hypokalemia, and infection signs. In septic shock, consider low-dose (200-300 mg/day) with fludrocortisone if refractory. Use buffered solution for IV; avoid mixing with other drugs in same solution (compatibility data limited). |
| Patient Advice | Take exactly as prescribed; do not stop suddenly without doctor's guidance as this can cause serious withdrawal symptoms. · Report any signs of infection (fever, sore throat) or unusual bruising/bleeding immediately. · Monitor blood sugar if diabetic; corticosteroids can raise blood glucose. · Avoid live vaccines while on this medication. · Carry a medical alert card or wear a bracelet indicating you are on corticosteroid therapy. |